<DOC>
	<DOCNO>NCT01446848</DOCNO>
	<brief_summary>The purpose study investigate effect iron supplementation patient pulmonary arterial hypertension iron deficiency .</brief_summary>
	<brief_title>Oral Iron Supplementation Pulmonary Hypertension</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) chronic disease associate upregulation hypoxia inducible-factor-1alpha ( HIF-1alpha ) functional iron deficiency . The investigator propose prospective , single-arm , open-label intervention determine whether oral iron supplementation patient pulmonary arterial hypertension reduce marker HIF activation improve clinical parameter disease . After baseline visit , patient give ferrous sulfate tablet take orally 3 month . Outcome data collect baseline visit end 3-month study period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>age 21 old diagnosis idiopathic pulmonary arterial hypertension iron deficiency ( transferrin saturation &lt; 20 % serum ferritin &lt; 100 ug/l ) active infection , malignancy , bleed hemochromatosis chronic inflammatory autoimmune disease currently take experimental/study medication , erythropoietin , iron supplementation , immunosuppressant allergy iron</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>iron deficiency</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>iron supplement</keyword>
	<keyword>ferrous sulfate</keyword>
</DOC>